Lou has decades of experience advising biotechnology, pharmaceutical, and life science clients on all aspects of patent law and related business matters.
Lou works with innovators engaged in highly technical fields, including CRISPR, cell therapy, immunotherapeutics, medical devices, pharmaceuticals, stem cells, biofuels, regenerative medicine, and transgenic animals. Prior to joining the firm, Lou was a patent examiner at the USPTO.
Aileron Therapeutics, Charleston Laboratories, Curemark, Gadeta B.V., BioNTech, Myeloid Therapeutics, Stoke Therapeutics, and TCR2 Therapeutics.
• |
Anterra Capital, Apple Tree Partners, F-Prime Capital, Flagship Pioneering, Newpath Partners, Novo Ventures, Oxford Science Innovation, RTW Investments, Samsara Biocapital, SR One, UPMC Enterprises, Venrock, Vida Ventures, and other venture and investment funds in IP diligence matters. |
• | Have supported more than 100 clients undergoing IP diligence for a venture round of investment. |
• |
Aileron Therapeutics, Beam Therapeutics, BioNtech, Cargo Therapeutics, Graphite Bio, Neon Therapeutics, Precigen, Prime Medicine, Recursion Pharmaceuticals, Stoke Therapeutics, and TCR2 Therapeutics on IP matters related to their public offerings. |
• |
4D Pharma on IP matters related to their cross-border merger into a SPAC and NASDAQ listing. |
• | B-Mogen Biotechnologies, CellPoint, Delinia, Future Health Works, Midori, MiroBio, Neon Therapeutics, NeuroCycle Therapeutics, Totient, each leading to an acquisition by a major biotech company. |
Dr. Louis D. Lieto is the leader of the patents and innovations department at Wilson Sonsini Goodrich & Rosati and is a partner in the firm’s Boston and Washington, D.C., offices. Lou advises biotechnology and pharmaceutical companies on strategic patent counseling, global patent portfolio development and management, and IP counseling for M&A and capital markets in complex life science fields.
Lou received his Ph.D. from the University of Kentucky, where he focused on characterizing the molecular and genetic basis of hereditary disease. Subsequently, Lou completed his postdoctoral fellowship in immunology at the National Institute of Allergy and Infectious Diseases (NIAID).
Prior to joining Wilson Sonsini, Lou was a patent examiner at the U.S. Patent and Trademark Office where he examined applications for inventions encompassing proteins, DNA vectors, nucleic acid vaccines, immune cell therapy, stem cell therapy, transgenic animals, and gene therapy.
Dr. Louis D. Lieto is the leader of the patents and innovations department at Wilson Sonsini Goodrich & Rosati and is a partner in the firm’s Boston and Washington, D.C., offices. Lou advises biotechnology and pharmaceutical companies on strategic patent counseling, global patent portfolio development and management, and IP counseling for M&A and capital markets in complex life science fields.
Lou received his Ph.D. from the University of Kentucky, where he focused on characterizing the molecular and genetic basis of hereditary disease. Subsequently, Lou completed his postdoctoral fellowship in immunology at the National Institute of Allergy and Infectious Diseases (NIAID).
Prior to joining Wilson Sonsini, Lou was a patent examiner at the U.S. Patent and Trademark Office where he examined applications for inventions encompassing proteins, DNA vectors, nucleic acid vaccines, immune cell therapy, stem cell therapy, transgenic animals, and gene therapy.